Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $12.3333.
A number of research analysts recently commented on the stock. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Monday, April 20th.
Get Our Latest Report on DiaMedica Therapeutics
Institutional Inflows and Outflows
DiaMedica Therapeutics Stock Performance
Shares of DMAC stock opened at $5.69 on Friday. The firm’s 50-day moving average is $6.09 and its 200-day moving average is $7.37. The stock has a market cap of $306.58 million, a price-to-earnings ratio of -8.01 and a beta of 0.97. DiaMedica Therapeutics has a 52-week low of $3.47 and a 52-week high of $10.42.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Sell-side analysts predict that DiaMedica Therapeutics will post -0.86 EPS for the current fiscal year.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.
DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
